Blackstone to sell Japanese Alinamin to MBK Partners for $2.17b

Private equity giant Blackstone is finalising the sale of Japanese supplement maker Alinamin Pharmaceutical to South Korea’s MBK Partners for 350 billion yen ($2.17 billion), according to a source with knowledge of the deal.

An official announcement is expected soon, but the parties involved – Blackstone, MBK Partners, and Alinamin – have declined to comment publicly.

Blackstone acquired Alinamin in August 2020 when it was a subsidiary of the Japanese pharmaceutical company Takeda. This news comes after an earlier report by Nikkei on Tuesday about Blackstone’s intention to sell Alinamin.

MBK Partners, a North Asian buyout fund, aims to leverage its expertise in consumer goods acquisitions to enhance Alinamin’s value proposition.

Attribution: Reuters